Psychiatric comorbidity and quality of life in patients with epilepsy on anti‑epileptic monotherapy and polytherapy

Abstract

 

Objective: The bio‑psycho‑social factors affecting the quality of life in patients with epilepsy can be numerous but are often overlooked. The behavioral side effects of anti‑seizure medications can be one such potential factor. The aim of the study is to address the effect of the number of anti‑seizure medications on the development of psychiatric comorbidity and quality of life in patients with adequate seizure control. Materials and Methods: The study recruited 100 participants with generalized tonic‑clonic seizures from a tertiary care center in North India, who were seizure‑free from the last 1 month. The study participants were divided into two groups based on whether they were on monotherapy or polytherapy. The two groups were matched for their socio‑demographic and clinical profile. We assessed for psychiatric comorbidity in each group using Mini International Neuropsychiatric Interview. All the study participants were given Hindi translated version of quality of life in the epilepsy‑31 questionnaire for objective assessment of the quality of life. Results: The patients receiving anti‑epileptic polytherapy had significantly higher prevalence of psychiatric comorbidity than patients on monotherapy. Furthermore, the patients on polytherapy scored significantly less on the cognitive domain of quality of life as well as the overall quality of life domain in the epilepsy‑31 questionnaire. Conclusion: The patients with epilepsy must be evaluated for psychiatric comorbidity and side effect profile of anti‑seizure medications to improve the quality of life. This is particularly more important for patients who are on anti‑epileptic polytherapy even if the seizure control is adequate.

Keywords: Epilepsy, Psychiatric comorbidity, Quality of life